The outlook for pharma M&A continues to be strong, writes Michael Jewell.
Michael Jewell
Advertisement
Michael Jewell is Partner, Head of Healthcare & Life Sciences at Cavendish Corporate Finance
Articles by Michael Jewell
Advertisement
Latest Updated Articles
M&A: Range of Fundamental Factors Will Drive Strong Deal FlowPublished: April 2nd 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
FDA Approves Bayer’s Lynkuet as First Dual Neurokinin Antagonist for Menopausal Hot Flashes
2
Direct-to-patient: pharma’s next power move
3
TrumpRx and the Dawn of Direct-to-Consumer Commercialization
4
AI Becomes Pharma’s New Operating System: Q&A with causaLens’ CEO and Co-Founder Darko Matovski
5
